Andrea J. Pruijssers

Andrea J. Pruijssers

Auto-generated profile, based on publicly available information

Andrea J. Pruijssers

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
TSTimothy Sheahan
Timothy Sheahan
ASAmy C. Sims
Amy C. Sims
SZShuntai Zhou
Shuntai Zhou
RGRachel L. Graham
Rachel L. Graham
APAndrea J. Pruijssers
Andrea J. Pruijssers
RBRalph S. Baric
Ralph S. Baric
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c bat-CoVs, as well as increased potency against a CoV bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC prodrug (β-d-N4-hydroxycytidine-5′-isopropyl ester), improved pulmonary function and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral, but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple CoVs and oral bioavailability highlights its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic CoVs.

1 July 2020 in Cell Reports
Verified
Journal Article
Open access
APAndrea J. Pruijssers
Andrea J. Pruijssers
AGAmelia S. George
Amelia S. George
ASAlexandra Schäfer
Alexandra Schäfer
SLSarah R. Leist
Sarah R. Leist
LGLisa Gralinski
Lisa Gralinski
TSTimothy Sheahan
Timothy Sheahan
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 μM). Weaker activity is observed in Vero E6 cells (EC50 = 1.65 μM) because of their low capacity to metabolize RDV. To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase of SARS-CoV-2. In mice infected with the chimeric virus, therapeutic RDV administration diminishes lung viral load and improves pulmonary function compared with vehicle-treated animals. These data demonstrate that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clinical testing for treatment of COVID-19.

19 January 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JGJennifer Gribble
Jennifer Gribble
LSLaura J. Stevens
Laura J. Stevens
MAMaria L. Agostini
Maria L. Agostini
JAJordan Anderson-Daniels
Jordan Anderson-Daniels
JCJames D. Chappell
James D. Chappell
MDMark R. Denison
Mark R. Denison
Recombination is proposed to be critical for coronavirus (CoV) diversity and emergence of SARS-CoV-2 and other zoonotic CoVs. While RNA recombination is required during normal CoV replication, the mechanisms and determinants of CoV recombination are not known. CoVs encode an RNA proofreading exoribonuclease (nsp14-ExoN) that is distinct from the CoV polymerase and is responsible for high-fidelity RNA synthesis, resistance to nucleoside analogues, immune evasion, and virulence. Here, we demonstrate that CoVs, including SARS-CoV-2, MERS-CoV, and the model CoV murine hepatitis virus (MHV), generate extensive and diverse recombination products during replication in culture. We show that the MHV nsp14-ExoN is required for native recombination, and that inactivation of ExoN results in decreased recombination frequency and altered recombination products. These results add yet another critical function to nsp14-ExoN, highlight the uniqueness of the evolved coronavirus replicase, and further emphasize nsp14-ExoN as a central, completely conserved, and vulnerable target for inhibitors and attenuation of SARS-CoV-2 and future emerging zoonotic CoVs.

3 August 2022 in Science Translational Medicine
Verified
Journal Article
Open access
LSLaura J. Stevens
Laura J. Stevens
APAndrea J. Pruijssers
Andrea J. Pruijssers
HLHery W. Lee
Hery W. Lee
CGCalvin Gordon
Calvin Gordon
ETEgor Petrovitch Tchesnokov
Egor Petrovitch Tchesnokov
MDMark R. Denison
Mark R. Denison
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Thus, it is critical to understand factors that promote or prevent RDV resistance. We passaged SARS-CoV-2 in the presence of increasing concentrations of GS-441524, the parent nucleoside of RDV. After 13 passages, we isolated three viral lineages with phenotypic resistance as defined by increases in half-maximal effective concentration from 2.7- to 10.4-fold. Sequence analysis identified nonsynonymous mutations in nonstructural protein 12 RNA-dependent RNA polymerase ( nsp12 -RdRp): V166A, N198S, S759A, V792I, and C799F/R. Two lineages encoded the S759A substitution at the RdRp Ser 759 -Asp-Asp active motif. In one lineage, the V792I substitution emerged first and then combined with S759A. Introduction of S759A and V792I substitutions at homologous nsp12 positions in murine hepatitis virus demonstrated transferability across betacoronaviruses; introduction of these substitutions resulted in up to 38-fold RDV resistance and a replication defect. Biochemical analysis of SARS-CoV-2 RdRp encoding S759A demonstrated a roughly 10-fold decreased preference for RDV-triphosphate (RDV-TP) as a substrate, whereas nsp12 -V792I diminished the uridine triphosphate concentration needed to overcome template-dependent inhibition associated with RDV. The in vitro–selected substitutions identified in this study were rare or not detected in the greater than 6 million publicly available nsp12 -RdRp consensus sequences in the absence of RDV selection. The results define genetic and biochemical pathways to RDV resistance and emphasize the need for additional studies to define the potential for emergence of these or other RDV resistance mutations in clinical settings.

1 June 2019 in Journal of Autoimmunity
Verified
Journal Article
Closed access
MHMaxwell J. Heinrich
Maxwell J. Heinrich
CPCaroline A. Purcell
Caroline A. Purcell
APAndrea J. Pruijssers
Andrea J. Pruijssers
YZYang Zhao
Yang Zhao
CSCharles F. Spurlock
Charles F. Spurlock
TAThomas M. Aune
Thomas M. Aune

27 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
APAndrea J. Pruijssers
Andrea J. Pruijssers
AGAmelia S. George
Amelia S. George
ASAlexandra Schäfer
Alexandra Schäfer
SLSarah R. Leist
Sarah R. Leist
LGLisa E. Gralinksi
Lisa E. Gralinksi
TSTimothy Sheahan
Timothy Sheahan
SUMMARY: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 as the causative agent of the novel pandemic viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for safe, broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC 50 = 0.01 μM). Weaker activity was observed in Vero E6 cells (EC 50 = 1.65 μM) due to their low capacity to metabolize RDV. To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase, of SARS-CoV-2. In mice infected with chimeric virus, therapeutic RDV administration diminished lung viral load and improved pulmonary function as compared to vehicle treated animals. These data provide evidence that RDV is potently active against SARS-CoV-2 in vitro and in vivo , supporting its further clinical testing for treatment of COVID-19.